AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19125264 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DRSP
Number of subjects: 160
Study 19125264 — intervention group
Group type: COMPARATOR
Intervention: EE/GSD
Number of subjects: 160
Study 19125264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 17510720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival retraction cord systems (including untreated, medium-braided, and epinephrine-impregnated cords)
Number of subjects: 16
Study 17510720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival retraction cord medicaments
Number of subjects: 16
Study 17510720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord thicknesses
Number of subjects: 16
Study 15715101 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 2‐5.2 mg/body mass unit for 1‐10 years (average 4 years)
Number of subjects: 1033
Study 15715101 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 1033
Study 11472741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day
Number of subjects: 40
Study 11472741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9602957 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 50 mg, 100 mg, 350 mg once daily or 150 mg every 12 hours
Number of subjects: 57
Study 9602957 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg, 800 mg, 1,200 mg once daily
Number of subjects: 57
Study 9602957 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan (various doses)
Number of subjects: 57
Study 8296941 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site medical care at the methadone treatment clinic (n = 25)
Number of subjects: 51
Study 8296941 — intervention group
Group type: COMPARATOR
Intervention: Referral to a nearby clinic (n = 26)
Number of subjects: 51
Study 29232162 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR342434 (SAR-Lis)
Number of subjects: 505
Study 29232162 — intervention group
Group type: COMPARATOR
Intervention: Ly‐Lis (Insulin Lispro)
Number of subjects: 505
Study 27520922 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Schizophrenia Psychoeducation Program (FSPP)
Number of subjects: 59
Study 27520922 — intervention group
Group type: COMPARATOR
Intervention: Control (services as usual, antipsychotic medication)
Number of subjects: 59
Study 25722080 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSi(™) simulator
Number of subjects: 42
Study 23211877 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg daily aglycone hypocotyl soy isoflavone supplementation
Number of subjects: 403
Study 23211877 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg daily aglycone hypocotyl soy isoflavone supplementation
Number of subjects: 403
Study 23211877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 20067964 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone plus American Diabetes Association (ADA) dietary advice (Pio+ADA)
Number of subjects: 51
Study 20067964 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone plus portion-controlled diet (Pio+PC)
Number of subjects: 51
Study 20067964 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin plus ADA advice (Met+ADA)
Number of subjects: 51
Study 18483440 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly participants stepping up
Number of subjects: 25
Study 16166774 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 10.5 mg
Number of subjects: 31
Study 16166774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg
Number of subjects: 31
Study 16166774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 14578240 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary diabetes outreach service (six monthly visits by a traveling team of specialist physicians, nurses, dieticians, and a pharmacist)
Number of subjects: 379
Study 14578240 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary diabetes outreach service
Number of subjects: 379
Study 14578240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 379
Study 14578240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 379
Study 11113723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (daily target dose 32.5-35 mg)
Number of subjects: 3164
Study 11113723 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lisinopril (daily target dose 2.5-5.0 mg)
Number of subjects: 3164
Study 11113723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril
Number of subjects: 3164
Study 11113723 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lisinopril
Number of subjects: 3164
Study 9096443 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 40
Study 9096443 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated for the first year)
Number of subjects: 40
Study 8210967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin combined with 5 g of colestipol
Number of subjects: 57
Study 8210967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin combined with 10 g of colestipol
Number of subjects: 57
Study 8210967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2946972 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg with 5 ml of 1% xylocaine
Number of subjects: 60
Study 2946972 — intervention group
Group type: COMPARATOR
Intervention: Morphine with normal saline 5 ml followed by xylocaine
Number of subjects: 60
Study 2946972 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected epidurally
Number of subjects: 60
Study 30935555 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathy (IH)
Number of subjects: 60
Study 30935555 — intervention group
Group type: COMPARATOR
Intervention: Control/placebo
Number of subjects: 60
Study 30458826 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-scale with cutoff score >=4 points
Number of subjects: 485
Study 30458826 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-scale
Number of subjects: 485
Study 30458826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-researcher PD-scale assessments
Number of subjects: 485
Study 26808145 — intervention group
Group type: EXPERIMENTAL
Intervention: iPeer2Peer program (peer mentorship program with 10 Skype video calls over 8 weeks)
Number of subjects: 28
Study 26808145 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist control)
Number of subjects: 28
Study 25213578 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator group
Number of subjects: 90
Study 25213578 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods group
Number of subjects: 90
Study 22618435 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-volume (non-spiral) mode
Number of subjects: 64
Study 22618435 — intervention group
Group type: COMPARATOR
Intervention: Helical mode
Number of subjects: 64
Study 20399477 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-word test (5WT)
Number of subjects: 504
Study 18204390 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic visits
Number of subjects: 818
Study 18204390 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physician (PCP) visits
Number of subjects: 818
Study 18204390 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner visits for headache and neck complaints
Number of subjects: 818
Study 15737773 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with Recombivax HB, Td, and MMR vaccines
Number of subjects: 197
Study 15737773 — intervention group
Group type: COMPARATOR
Intervention: Nonconcomitant vaccination (HB given at a separate time from Td and MMR)
Number of subjects: 197
Study 11828239 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 75
Study 11828239 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength
Number of subjects: 75
Study 11828239 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength (normalized per leg lean tissue mass)
Number of subjects: 75
Study 11828239 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion strength
Number of subjects: 75
Study 11828239 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength as predictor
Number of subjects: 75
Study 9951494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid
Number of subjects: 238
Study 9951494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 9951494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 238
Study 8532984 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation of missing responses using the approximate Bayesian bootstrap
Number of subjects: 0
Study 8532984 — intervention group
Group type: COMPARATOR
Intervention: Standard endpoint method
Number of subjects: 0
Study 2268796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nifedipine (100 micrograms)
Number of subjects: 15
Study 2268796 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-based control solvent
Number of subjects: 15
Study 215386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextranomer
Number of subjects: 17
Study 215386 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 17
Study 215386 — intervention group
Group type: COMPARATOR
Intervention: Sugar and egg white
Number of subjects: 17
Study 30831287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 1 (meningothelial vs fibrous)
Number of subjects: 241
Study 30831287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 2 (fibrous vs transitional)
Number of subjects: 241
Study 30831287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 3 (meningothelial vs transitional)
Number of subjects: 241
Study 30831287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 4 (meningothelial vs fibrous vs transitional)
Number of subjects: 241
Study 28936951 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 49
Study 28936951 — intervention group
Group type: COMPARATOR
Intervention: NPPV
Number of subjects: 49
Study 26328533 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18
Study 26328533 — intervention group
Group type: COMPARATOR
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 18
Study 25141084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 36
Study 25141084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 36
Study 25141084 — intervention group
Group type: COMPARATOR
Intervention: No Practice (NP)
Number of subjects: 36
Study 22040002 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 44
Study 22040002 — intervention group
Group type: COMPARATOR
Intervention: Control (uninfected, healthy)
Number of subjects: 44
Study 19293008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (400 mg/kg/d for 5 days)
Number of subjects: 61
Study 19293008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg/d for 5 days)
Number of subjects: 61
Study 19293008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (200 mg/kg/d for 5 days)
Number of subjects: 61
Study 19293008 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety end point across all treatment groups
Number of subjects: 61
Study 17440206 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions prompting a nontrait inference (truth or lie?) for self-informants
Number of subjects: 0
Study 17440206 — intervention group
Group type: COMPARATOR
Intervention: Instructions prompting a nontrait inference (truth or lie?) for third-party informants
Number of subjects: 0
Study 17440206 — intervention group
Group type: COMPARATOR
Intervention: Cognitive load as an explanation for effects
Number of subjects: 0
Study 16351368 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental induction of threat
Number of subjects: 0
Study 16351368 — intervention group
Group type: COMPARATOR
Intervention: Acceptance condition
Number of subjects: 0
Study 16351368 — intervention group
Group type: EXPERIMENTAL
Intervention: State Orientation x Stress interaction
Number of subjects: 0
Study 16351368 — intervention group
Group type: EXPERIMENTAL
Intervention: State Orientation x Stress effect
Number of subjects: 0
Study 12126682 — intervention group
Group type: COMPARATOR
Intervention: Knee splint
Number of subjects: 81
Study 12126682 — intervention group
Group type: EXPERIMENTAL
Intervention: No splint
Number of subjects: 81
Study 9477057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20
Study 9477057 — intervention group
Group type: COMPARATOR
Intervention: Intralipos infusion
Number of subjects: 20
Study 9477057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in vitro
Number of subjects: 20
Study 9477057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol effect on intracellular calcium
Number of subjects: 20
Study 8550251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg per os)
Number of subjects: 11
Study 8550251 — intervention group
Group type: COMPARATOR
Intervention: Control (without propranolol)
Number of subjects: 11
Study 2213104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemo-endocrine therapy (initial treatment)
Number of subjects: 143
Study 2213104 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (control)
Number of subjects: 143
Study 2213104 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (control) after crossover to chemotherapy
Number of subjects: 143
Study 2213104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (both arms)
Number of subjects: 143
Study 2213104 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy (initial endocrine therapy)
Number of subjects: 143
Study 2213104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) (initial endocrine therapy)
Number of subjects: 143
Study 6780707 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 0
Study 6780707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactalbumin hydrolysate
Number of subjects: 0
Study 6780707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein hydrolysate
Number of subjects: 0
Study 6780707 — intervention group
Group type: COMPARATOR
Intervention: AA mixtures
Number of subjects: 0
Study 29911352 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine
Number of subjects: 19
Study 29911352 — intervention group
Group type: COMPARATOR
Intervention: Air-cooling alone
Number of subjects: 19
Study 28459239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupotomy
Number of subjects: 60
Study 28459239 — intervention group
Group type: COMPARATOR
Intervention: Electro-acupuncture (EA)
Number of subjects: 60
Study 24569698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-care coaching intervention delivered by medical assistants
Number of subjects: 270
Study 24569698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 270
Study 22422824 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 917
Study 22422824 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF with escalated-dose cytarabine
Number of subjects: 917
Study 19675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models (BHMs) for cost-effectiveness analysis
Number of subjects: 1732
Study 19675321 — intervention group
Group type: COMPARATOR
Intervention: Standard bivariate regression models
Number of subjects: 1732
Study 18503773 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 1000/1200 mg/day for 24 weeks
Number of subjects: 516
Study 18503773 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 24 weeks
Number of subjects: 516
Study 15924511 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise therapy (n = 87)
Number of subjects: 176
Study 15924511 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 89)
Number of subjects: 176
Study 12908904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sip-feed supplement prescribed (120 ml, 22.5 g protein, 2260 kJ (540 kcal) energy/d) three times per day during hospital stay
Number of subjects: 381
Study 12908904 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 381
Study 10947756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 7.5 mg combined with preservative‐free ketamine 25 mg
Number of subjects: 30
Study 10947756 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 10 mg alone
Number of subjects: 30
Study 8818207 — intervention group
Group type: COMPARATOR
Intervention: 15% O2 gas mixture during 100 W and 150 W hindlimb exercises (protocol 1)
Number of subjects: 0
Study 8818207 — intervention group
Group type: COMPARATOR
Intervention: 15% and 10% O2 mixtures during unloaded (0 W) cycling (protocol 2)
Number of subjects: 0
Study 8818207 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing (normoxia)
Number of subjects: 0
Study 1502426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine therapy in addition to standard therapy
Number of subjects: 30
Study 1502426 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 30
Study 6488686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg) before ketamine
Number of subjects: 8
Study 6488686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) before ketamine
Number of subjects: 8
Study 30807424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (2% transurethral)
Number of subjects: 116
Study 30261294 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multicomponent physical activity program (strength, balance, aerobic) led by trained volunteers or delivered via DVD with coaching and oversight by a fitness professional
Number of subjects: 1130
Study 30261294 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multicomponent physical activity program
Number of subjects: 1130
Study 26509827 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP
Number of subjects: 71
Study 26509827 — intervention group
Group type: COMPARATOR
Intervention: Control (simulation of PRP administration)
Number of subjects: 71
Study 26509827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 26509827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 26509827 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 71
Study 26605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Live varicella zoster vaccine
Number of subjects: 54
Study 26605507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22732720 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at P6
Number of subjects: 130
Study 22732720 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic drug therapy (control group)
Number of subjects: 130
Study 20043005 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline
Number of subjects: 31
Study 20043005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18777490 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2838
Study 18777490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 15854783 — intervention group
Group type: EXPERIMENTAL
Intervention: High cortisol responses
Number of subjects: 20
Study 15854783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trait avoidance
Number of subjects: 20
Study 12441832 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and toileting intervention (4 times a day, 5 days a week, for 32 weeks)
Number of subjects: 51
Study 12441832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 10518670 — intervention group
Group type: EXPERIMENTAL
Intervention: SA (5%)
Number of subjects: 4
Study 10518670 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC (10%)
Number of subjects: 4
Study 10518670 — intervention group
Group type: EXPERIMENTAL
Intervention: Duofilm (16.7%)
Number of subjects: 4
Study 10518670 — intervention group
Group type: EXPERIMENTAL
Intervention: TSSS (2%)
Number of subjects: 4
Study 10518670 — intervention group
Group type: COMPARATOR
Intervention: SAO (10%)
Number of subjects: 4
Study 10518670 — intervention group
Group type: COMPARATOR
Intervention: Salic (2.5%)
Number of subjects: 4
Study 7577874 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pumiced test groups (no pumice prophylaxis)
Number of subjects: 726
Study 7577874 — intervention group
Group type: COMPARATOR
Intervention: Pumiced control groups (with pumice prophylaxis)
Number of subjects: 726
Study 2031502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and prednisone (CAP)
Number of subjects: 94
Study 2031502 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone (CFP)
Number of subjects: 94
Study 6222183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 7
Study 6222183 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 7
Study 6222183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30819689 — intervention group
Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT)
Number of subjects: 889
Study 30819689 — intervention group
Group type: COMPARATOR
Intervention: Control group (open angles)
Number of subjects: 889
Study 30819689 — intervention group
Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT) among PACS with all four quadrants closed
Number of subjects: 889